[HTML][HTML] Chimeric antigen receptor T cells: a novel therapy for solid tumors

S Yu, A Li, Q Liu, T Li, X Yuan, X Han, K Wu - Journal of hematology & …, 2017 - Springer
The chimeric antigen receptor T (CAR-T) cell therapy is a newly developed adoptive
antitumor treatment. Theoretically, CAR-T cells can specifically localize and eliminate tumor …

[HTML][HTML] Guidelines for the diagnosis and treatment of malignant pleural mesothelioma

N Van Zandwijk, C Clarke, D Henderson… - Journal of thoracic …, 2013 - ncbi.nlm.nih.gov
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …

Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010

C Hooper, YCG Lee, N Maskell - Thorax, 2010 - thorax.bmj.com
Since the 2003 guideline, several clinically relevant studies have been published, allowing
new recommendations regarding image guidance of pleural procedures with clear benefits …

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis

K Hollevoet, JB Reitsma, J Creaney… - Journal of clinical …, 2012 - ascopubs.org
Purpose Mesothelin is currently considered the best available serum biomarker of malignant
pleural mesothelioma. To examine the diagnostic accuracy and use of serum mesothelin in …

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 …

HL Kindler, S Novello, A Bearz, GL Ceresoli… - The Lancet …, 2022 - thelancet.com
Background Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody–drug conjugate anetumab ravtansine …

Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients

EL Servais, C Colovos, L Rodriguez, AJ Bograd… - Clinical Cancer …, 2012 - AACR
Purpose: Mesothelin (MSLN) is a tumor-associated antigen, being investigated as a
biomarker and therapeutic target in malignant pleural mesothelioma (MPM). The biologic …

Recent advances in the diagnosis and management of malignant pleural effusions

JE Heffner, JS Klein - Mayo Clinic Proceedings, 2008 - Elsevier
Malignant pleural effusions (MPEs) are an important complication for patients with
intrathoracic and extrathoracic malignancies. Median survival after diagnosis of an MPE is 4 …

Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis

E Schillebeeckx, JP van Meerbeeck… - European Respiratory …, 2021 - Eur Respiratory Soc
Malignant pleural mesothelioma (MPM) is characterised by late-stage diagnosis and poor
prognosis. Currently, no screening tool is advocated and diagnosis is based on invasive …

Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung …

SS Kachala, AJ Bograd, J Villena-Vargas, K Suzuki… - Clinical cancer …, 2014 - AACR
Purpose: In an effort to identify molecular markers of tumor aggressiveness and therapeutic
targets in lung adenocarcinoma (ADC), we investigated the expression of mesothelin …

Malignant pleural mesothelioma: an update on biomarkers and treatment

M Ray, HL Kindler - Chest, 2009 - Elsevier
Although the insulating properties of asbestos have been known for millennia, the link
between asbestos exposure and mesothelioma was not recognized until 1960, when it was …